Promise Bio

AI‑powered epiproteomics platform for precision autoimmune disease medicine.

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

AI‑powered epiproteomics platform for precision autoimmune disease medicine.

Immunology

AI‑enhanced epiproteomics platform that analyzes PTMs from standard mass‑spectrometry data to generate explainable, clinically relevant insights.

Growing demand for AI‑driven biomarker discovery and patient stratification in autoimmune disease drug development.

Reliance on emerging AI models and regulatory acceptance of proteomics‑based diagnostics could delay commercialization.

Competes with proteomics service providers such as SomaLogic and Olink, but differentiates through deep PTM analysis and explainable AI.